Condensed Consolidated Statements of Operations and Comprehensive Loss (Unaudited) - USD ($)		3 Months Ended		6 Months Ended
		Feb. 28, 2022	Feb. 28, 2021	Feb. 28, 2022	Feb. 28, 2021
Income Statement [Abstract]
REVENUE		$ 7,631	$ 32,389	$ 22,436	$ 55,252
OPERATING EXPENSES
Research and development expenses		(114,896)	(157,594)	(261,179)	(304,565)
Sales and marketing expenses		(33,764)	(61,028)	(247,536)	(170,730)
General and administrative expenses		(1,110,932)	(2,524,760)	(2,781,422)	(5,477,927)
LOSS FROM OPERATIONS		(1,251,961)	(2,710,993)	(3,267,701)	(5,897,970)
Interest expense		(22,196)	(16,957)	(50,596)	(32,403)
(Loss) Gain on change in fair value of convertible notes		(1,076,830)	150,755	(1,181,330)	(330,288)
OTHER (EXPENSE) INCOME
Exchange difference, net		(30,974)		(6,054)
Other income – from related parties					1,823
Other income – from non-related parties		80	1,733	531	21,202
Non-operating income (expense)		(30,894)	1,733	(5,523)	23,025
LOSS BEFORE INCOME TAX		(2,381,881)	(2,575,462)	(4,505,250)	(6,237,636)
Income tax benefit		4,482	5,115	8,964	10,229
NET LOSS		(2,377,399)	(2,570,347)	(4,496,286)	(6,227,407)
OTHER COMPREHENSIVE LOSS
Foreign currency translation adjustment		35,460	35,791	11,083	35,584
TOTAL COMPREHENSIVE LOSS		$ (2,377,399)	$ (2,534,556)	$ (4,485,203)	$ (6,191,823)
Net loss per share - Basic and diluted		$ (0.02)	$ (0.02)	$ (0.03)	$ (0.05)
Weighted average number of shares of common stock outstanding - Basic and diluted	[1]	170,033,710	141,553,018	165,431,246	139,224,402

[1] Including 1,600,000 shares converted from convertible notes but not yet issued and 4,578,868 shares granted and vested but not yet issued for the period ended February 28, 2022; and including 58,333 shares that were granted and vested but not yet issued for the period ended February 28, 2021.